List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 205 studies with search of: "Alemtuzumab"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Biological: Alemtuzumab (Campath®, MabCampath®);   Biological: Alemtuzumab (Campath®, MabCampath®)
2 Recruiting Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Alemtuzumab (CAMPATH 1H) associated to G-CSF
3 Active, not recruiting Fludara Plus Alemtuzumab (Campath, MabCampath) vs Fludara Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Condition: B-Cell Lymphocytic Leukemia
Interventions: Biological: alemtuzumab (Campath, MabCampath); FluCAM [Fludara + Campath];   Biological: fludarabine phosphate (Fludara)
4 Active, not recruiting Safety and Efficacy of Campath in Nonmyeloablative Transplantation
Conditions: Lymphoma;   Leukemia
Interventions: Drug: Campath-1 H (Alemtuzumab);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
5 Recruiting Alemtuzumab and Pentostatin In T-Cell Neoplasms
Conditions: Lymphoma;   Leukemia
Interventions: Drug: Pentostatin;   Drug: Alemtuzumab
6 Recruiting Alemtuzumab + Rituximab Consolidation in CLL
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Rituximab;   Drug: Alemtuzumab
7 Recruiting A Phase I Study of Alemtuzumab Delivered Intraperitoneally in Patients With Relapsed Ovarian Cancer
Condition: Recurrent Ovarian Cancer Not Responsive to Standard Chemo
Interventions: Drug: Alemtuzumab;   Drug: Alemtuzumab
8 Recruiting Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Conditions: Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune
Intervention: Drug: Alemtuzumab, Rituximab
9 Completed Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Condition: B Cell Chronic Lymphocytic Leukemia
Intervention: Drug: alemtuzumab
10 Recruiting Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
11 Active, not recruiting A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
Condition: B-Cell Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine phosphate;   Drug: Alemtuzumab
12 Active, not recruiting Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy
Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Biological: Alemtuzumab (Campath-1H)
13 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath® (Registered Trademark))
14 Recruiting Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Condition: Peripheral T-Cell Lymphomas
Intervention: Drug: Alemtuzumab (Campath-1H)
15 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
16 Recruiting Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Campath-1H
17 Recruiting Alemtuzumab (Campath® (Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoprofilerative Disorders
Intervention: Drug: Alemtuzumab (Campath)
18 Completed Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath
Conditions: Adult Acute Lymphocytic Leukemia T-Cell;   Lymphoma, Lymphoblastic
Interventions: Drug: Alemtuzumab (MabCampath);   Drug: Cladribine
19 Active, not recruiting A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
20 Recruiting Alemtuzumab and CHOP in T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Peripheral
Interventions: Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;   Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services